The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Evaluating the optimal duration of lenalidomide maintenance after autoSCT using data from Myeloma XI
In this video, Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, shares some insights into the role of lenalidomide maintenance therapy post-autologous stem cell transplantation (autoSCT) in patients with multiple myeloma. Dr Pawyln discusses an analysis which used data from the Myeloma XI trial (NCT01554852) to determine whether lenalidomide maintenance could be discontinued earlier. Results demonstrated a clear benefit with continuing lenalidomide maintenance beyond three years, although a longer follow-up of this data is needed. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen: Consultancy, Honoraria, Other: Travel support; Sanofi: Consultancy, Honoraria; Celgene/BMS: Consultancy, Honoraria; Abbvie: Consultancy.
